Alpenglow Biosciences provides a 3D pathology platform that utilizes Hybrid Open Top Light Sheet (HOTLS) microscopy and AI analysis to deliver high-resolution imaging of biological samples. This technology enables researchers to visualize complex tissue structures and cellular distributions, enhancing drug development and clinical diagnostics by revealing insights that traditional 2D histology methods cannot capture.

The startup develops analytical testing devices that utilize combination light obscuration technology for sub-visible particle testing, which is essential for ensuring patient safety in parenteral preparations. Their services support stability testing, drug formulation, and in-process control during manufacturing, enabling clients to meet regulatory requirements and enhance product quality.

Bit.bio develops a cell coding platform that utilizes deterministic programming to create and manufacture any human cell type with precision and scalability. This technology addresses the need for consistent and reliable cell production for research and therapeutic applications, enabling the development of next-generation treatments.

CellFE develops a microfluidics-based device that delivers gene-editing molecules to enhance cell health and yield during the manufacturing of cell therapies. This technology addresses the challenges of long production times and high costs, enabling scalable and efficient processes from research to commercial applications.

Curi Bio develops biosystem platforms that integrate human cells and data to create 3D tissue models for drug discovery and disease modeling. Their technology enables accurate testing of drug safety and efficacy, addressing the challenges of predictive accuracy in preclinical drug development.

Resipher is a real-time, non-invasive oxygen consumption rate (OCR) monitoring system that utilizes patented miniature ultra-sensitive oxygen probes to continuously measure mitochondrial respiration in standard 96-well plates. This technology provides researchers with critical insights into cellular metabolism, enabling long-term tracking of metabolic activity without disturbing the cell culture environment.

Vernal Biosciences provides an end‑to‑end CDMO platform for mRNA and lipid nanoparticle (LNP) production, covering sequence design, custom synthesis, GMP manufacturing, formulation, and analytical services. Their data‑driven Quality‑by‑Design system delivers high‑purity, high‑yield mRNA material—both catalog and custom—scaled from research‑grade to clinical‑grade batches, enabling biotech and pharma companies to accelerate preclinical and clinical development.

Virica Biotech develops Viral Sensitizers (VSE™), patented small molecules that transiently attenuate innate cellular antiviral defenses to enhance viral vector production in gene therapy and vaccine applications. By improving yields and scalability across over 50 evaluated applications, VSEs enable more efficient manufacturing processes for critical viral products.